PENNVAX-GP (HIV DNA vaccine) / Inovio  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PENNVAX-GP (HIV DNA vaccine) / Inovio
NCT03606213: Therapeutic Vaccination in Treated HIV Disease

Completed
1/2
56
US
PENNVAX-GP, HIV DNA vaccine, INO-6145, INO-9012, IL-12 DNA adjuvant, CELLECTRA® 2000, Electroporation device
Steven Deeks, National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles, Inovio Pharmaceuticals
HIV-1-infection
05/21
05/21

Download Options